Form 8-K
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 25, 2003

CardioGenesis Corporation

(Exact Name of Registrant as Specified in Charter)
         
California
(State or Other Jurisdiction
of Incorporation)		   000-28288
(Commission
File Number) 		  77-0223740
(IRS Employer
Identification No.)
     
26632 Towne Centre Drive, Suite 320,    
Foothill Ranch, California
(Address of Principal Executive Offices)		   92610
(Zip Code)
     
Registrant’s telephone number, including area code:   (714) 649-5000
   

(Former Name or Former Address, if Changed Since Last Report)

 

TABLE OF CONTENTS

Item 7. Financial Information, Pro Forma Financial Information and Exhibits
Item 9. Regulation FD Disclosure
SIGNATURE
EXHIBIT INDEX
EXHIBIT 99.1

Table of Contents

Item 7. Financial Information, Pro Forma Financial Information and Exhibits

     (a)  Not applicable.

     (b)  Not applicable.

     (c)  Exhibits:

       Pursuant to General Instruction F of Form 8-K, the following documents are incorporated by reference herein and attached as exhibits hereto:
     
Exhibit   Description
 
99.1   Press Release of CardioGenesis Corporation, dated November 25, 2003.

Item 9. Regulation FD Disclosure

     On November 25, 2003, CardioGenesis issued a press release announcing an update on the FDA review of its PMR system.

     The information in this Current Report on Form 8-K, including the exhibit, is being furnished pursuant to Item 9, and shall not be deemed “filed” under the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities thereunder. Furthermore, the information in this Current Report on Form 8-K, including the exhibit, shall not be deemed to be incorporated by reference into the filings of the Registrant under the Securities Act of 1933, as amended.

 

Table of Contents

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this current report to be signed on its behalf by the undersigned hereunto duly authorized.

         
        CARDIOGENESIS CORPORATION
         
         
Date: November 25, 2003   By:   /s/ CHRISTINE G. OCAMPO
Christine G. Ocampo
Acting Chief Financial Officer, Secretary and Treasurer

 

Table of Contents

EXHIBIT INDEX

     
Exhibit   Description
 
99.1   Press Release of CardioGenesis Corporation, dated November 25, 2003.